These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 12562578)

  • 21. Administrative prescription review procedures and use of atypical antipsychotic medications in the Department of Veterans Affairs.
    Rosenheck R; Leslie D
    Ment Health Serv Res; 2003 Sep; 5(3):149-53. PubMed ID: 15224448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics.
    Corson PW; Nopoulos P; Miller DD; Arndt S; Andreasen NC
    Am J Psychiatry; 1999 Aug; 156(8):1200-4. PubMed ID: 10450260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Lee JH; Lee YH; Yang SJ; Yoon JS
    Clin Neuropharmacol; 2009; 32(5):243-9. PubMed ID: 19620849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
    Rosenheck R; Cramer J; Xu W; Grabowski J; Douyon R; Thomas J; Henderson W; Charney D
    Health Serv Res; 1998 Dec; 33(5 Pt 1):1237-61. PubMed ID: 9865219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maintenance antipsychotic medication patterns in outpatient schizophrenia patients: a naturalistic cohort study.
    Burns T; Christova L; Cooper S; Harrison G; McKendrick J; Laugharne R; Obuaya T; McCreadie R; O'Brien S; Perrington S; Stephenson D
    Acta Psychiatr Scand; 2006 Feb; 113(2):126-34. PubMed ID: 16423164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride.
    Linden M; Scheel T; Eich FX
    J Psychopharmacol; 2006 Nov; 20(6):815-23. PubMed ID: 16401647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicians' reasons for antipsychotic coprescribing.
    Sernyak MJ; Rosenheck R
    J Clin Psychiatry; 2004 Dec; 65(12):1597-600. PubMed ID: 15641863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use patterns for antipsychotic medications in medicaid patients with schizophrenia.
    McCombs JS; Nichol MB; Stimmel GL; Shi J; Smith RR
    J Clin Psychiatry; 1999; 60 Suppl 19():5-11; discussion 12-3. PubMed ID: 10507275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Ratner Y; Gibel A; Yorkov V; Ritsner MS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual atypical neuroleptic use: prescribing patterns at a Veterans Affairs outpatient clinic.
    Voris JC
    Manag Care Interface; 2004 Jun; 17(6):28-31. PubMed ID: 15287716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.
    Mishara AL; Goldberg TE
    Biol Psychiatry; 2004 May; 55(10):1013-22. PubMed ID: 15121486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of antipsychotic medication on psychiatric service utilization and cost.
    Rothbard A; Murrin MR; Jordan N; Kuno E; McFarland BH; Stroup TS; Morrissey JP; Stiles PG; Boothroyd RA; Merwin E; Shern DL
    J Ment Health Policy Econ; 2005 Jun; 8(2):83-93. PubMed ID: 15998980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atypical and typical neuroleptics in acute schizophrenia and related delusional disorders. Drug choice, switching and outcome under naturalistic treatment conditions.
    Gaebel W; Riesbeck M; Janssen B; Schneider F; Held T; Mecklenburg H; Sass H
    Eur Arch Psychiatry Clin Neurosci; 2003 Aug; 253(4):175-84. PubMed ID: 12910348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Quality of life in patients with schizophrenia: a study of 100 cases].
    Zouari L; Thabet JB; Elloumi Z; Elleuch M; Zouari N; Maâlej M
    Encephale; 2012 Apr; 38(2):111-7. PubMed ID: 22516268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assertive community treatment in veterans affairs settings: impact on adherence to antipsychotic medication.
    Valenstein M; McCarthy JF; Ganoczy D; Bowersox NW; Dixon LB; Miller R; Visnic S; Slade EP
    Psychiatr Serv; 2013 May; 64(5):445-51, 451.e1. PubMed ID: 23412131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atypical antipsychotic medication poisoning: an evidence-based consensus guideline for out-of-hospital management.
    Cobaugh DJ; Erdman AR; Booze LL; Scharman EJ; Christianson G; Manoguerra AS; Caravati EM; Chyka PA; Woolf AD; Nelson LS; Troutman WG
    Clin Toxicol (Phila); 2007 Dec; 45(8):918-42. PubMed ID: 18163235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic 6-month follow-up study.
    Wittorf A; Sickinger S; Wiedemann G; Klingberg S
    Arch Clin Neuropsychol; 2008 May; 23(3):271-82. PubMed ID: 18272323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.